Riskpilot← Back to searchSign inGet full accessIrsus AB
ABActiveOrg 5569784597Geijersgatan 4 BWholesale of pharmaceutical and medical goods · NACE 4646Est. 20140 employees
Revenue 2024
SEK 0
EBITDA margin
—
+72% vs 2023
Equity ratio
76.7%
Financial strength
Net profit 2024
SEK -17K
+85% vs 2023
| Revenue | SEK 0 | — |
| EBITDA | SEK -17K | +72% |
| Net profit | SEK -17K | +85% |
| Total assets | SEK 43K | -28% |
| Equity | SEK 33K | -34% |
| Employees | 0 | — |
Legal name
Irsus AB
Org number
5569784597
Legal form
Aktiebolag
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
31 juli 2014
Share capital
SEK 50 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Bolaget skall sälja en kylväst som ökar metabolismen hos användaren och sportrelaterade produkter samt därmed förenlig verksamhet.
Address
Geijersgatan 4 B
Email
lars.moberg@ekonomihusetmoberg.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Staff expenses | — | — | — | — | — |
| EBITDA | −19 | −14 | −66 | −60 | −17 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 |
| EBIT | −19 | −14 | −66 | −60 | −17 |
| Net financials | −3 | −3 | −3 | −121 | — |
| Profit before tax | −22 | −16 | −69 | −110 | −17 |
| Tax | −0 | −0 | −0 | −0 | −0 |
| Net profit | −22 | −16 | −69 | −110 | −17 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 287 | 318 | 279 | 60 | 43 |
| Equity | 28 | 50 | 50 | 50 | 33 |
| Long-term debt | 130 | 130 | 130 | 0 | 0 |
| Short-term debt | 129 | 138 | 99 | 10 | 10 |
| Total debt | 259 | 268 | 229 | 10 | 10 |
EBITDA margin
-1700000.0%
This company
15.8%
Market median
-10759594% vs market
20202024
Equity ratio
76.7%
This company
38.2%
Market median
+101% vs market
20202024
Return on equity
-51.5%
This company
18.4%
Market median
-380% vs market
20202024
Net profit margin
-1700000.0%
This company
8.1%
Market median
-20987754% vs market
20202024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20202024
Debt / equity
0.30×
This company
0.62×
Market median
+52% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
FO Liquidator | Liquidator | 2025 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Deputy Board Member | 2026 | |
| Board of Directors | 2026 | |
| Former (1) | ||
| Deputy Board Member | 2022 – 2024 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Irsus AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Felix Oskar Runer | Liquidator | 0 companies |
| Mattias Claes Skiöldebrand | Deputy Board Member | 0 companies |
| Lars Johan Gunnar Moberg | Deputy Board Member | 0 companies |
| Gustaf Erik Richard Philip Sörensen | Board of Directors | 0 companies |